Punnee PitisuttithumPhillip W. BermanBenjaluck PhonratPravan SuntharasamaiSuwanee RakthamLa Ong SrisuwanvilaiKrit HirunrasDwip KitayapornJaranit KaewkangwalSricharoen MigasenaHaynes W. SheppardElizabeth LiMarlene ChernowMichael L. PetersonRiri ShibataWilliam L. HeywardDonald P. FrancisMahidol UniversityVaxGen, Inc.Bangkok Metropolitan AdministrationViral Rickettsial Disease LaboratoryNovacea, Inc.Gilead Sciences Incorporated2018-07-242018-07-242004-09-01Journal of Acquired Immune Deficiency Syndromes. Vol.37, No.SUPPL. 1 (2004), 1160-1165152541352-s2.0-4444309788https://repository.li.mahidol.ac.th/handle/123456789/21578A phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane, CA), a bivalent subunit vaccine prepared by combining recombinant gp120 from a subtype B virus (HIV-1MN) with gp120 from a subtype E virus (HIV-1A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenic in humans. The optimal dose for humans in developing countries was 300 μg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1.Mahidol UniversityMedicineArticleSCOPUS10.1097/01.qai.0000136091.72955.4b